Drug-GPT Gives Marketers Access to Patient Experiences in Seconds
Talking Medicines has launched the first GPT for healthcare marketers, giving them access to vital insights about patients and HCPs within seconds through the world’s first curated patient voice GPT. Talking Medicines launched Drug-GPT on its PatientMetRx 2.0 platform, to provide healthcare advertising agencies with real-world insights about the lived experience, opinions, and sentiment of patients and HCPs. Via Talking Medicines’ database, subscribers can answer their own questions about how patients experience drugs and treatments compared to the perspective of HCPs, drawing on opinions and feelings about lived experiences, including demographics, diagnoses, treatments, and outcomes.
Jo Halliday, CEO and Co-founder of Talking Medicines said in a statement, “We are really excited by the potential of Drug-GPT to transform the way that healthcare advertising agencies analyze insights on complex patient and HCP social data. With structured and actionable insights delivered within seconds, it provides our customers with the edge to win business, create amazing content, and deliver successful campaigns. With Drug-GPT and PatientMetRx 2.0, we truly believe we can unlock the power of AI to transform healthcare marketing.”
Because Drug-GPT uses Talking Medicines’ social data alone, subscribed healthcare advertising agencies can secure instant and accurate insights more efficiently than with alternative solutions. Marketers can confidently use insights that are fully compliant with health sector regulations and backed by a suite of quality control processes for anything from informing new business pitches, developing winning strategies, inventing creative content, and monitoring the impact of critical market events on customer behavior.
Cognizant’s Generative AI Is Here
Cognizant Neuro AI is one of the first enterprise-scale generative AI platforms designed to help accelerate the adoption of generative AI technology and harness its business value in a flexible, secure, scalable, and responsible way. The platform’s models and tools can be used to build client specific tools all while helping firms better understand, consume, and customize AI models that drive business outcomes. The platform leverages Cognizant’s consulting, advisory, ecosystem partnership, digital studios, solutioning, and delivery capabilities, in conjunction with industry expertise, all to guide firms through their AI transition, from identifying company specific-use cases and operationalizing AI, to data engineering and continuous improvement.
“It is fast becoming clear that businesses must embrace AI without delay to remain competitive,” stated Prasad Sankaran, EVP of Cognizant’s Software and Platform Engineering. “This is an exciting moment, as Cognizant’s Neuro AI platform goes beyond proof of concept, aiming to accelerate the adoption of enterprise scale AI applications, increase ROI potential, minimize risks, and get to better business solutions, faster.”
The platform allows AI and software engineering teams to build flexible, reusable, safe, and secure solutions, and design conversational and generative user experiences, embedding AI models to create fully functioning apps—all supported across multi-platform, multi-cloud ecosystems. Cognizant Neuro AI includes development tooling and control components including API and access management, versioning, and auditing. The design is meant to help clients discover new business innovation vectors, create pathways to differentiated customer and employee experiences, reimagine and digitize business processes, and improve time to market at enterprise scale.
KAM Consulting and Boundless Life Sciences Convene
Boundless Commercial Consulting (BCC) is a new comprehensive consulting division of Boundless Life Sciences Group created in combination with KAM Consulting, led by Steve Mitchell. Mitchell is an industry veteran with over 30 years of experience in pharmaceutical marketing and commercial experience across business, portfolio, and strategic planning. He will continue to lead BCC as it offers services ranging from early-stage clinical development through late-stage lifecycle management and portfolio optimization, as well as provide critical brand, portfolio, and corporate market analysis, business planning, forecasting, and clinical and commercial operating planning support.
“Our offering matches up with the lifecycle of a drug, which is about 12 years,” stated Mitchell, Founder and CEO of BCC. “The Boundless structure supports innovation and the founders who drive it, which is why I am excited to be partnering on what’s next in our industry.”
ZoomRx Releases Another AI Chatbot for the Industry
Ferma, ZoomRx’s AI-powered conversational platform, has been designed specifically for healthcare professionals across the pharmaceutical, biotech, and medical device industries to provide rapid and accurate answers to any life sciences question. The ground-breaking platform is intended to elevate decision-making processes for industry professionals and organizations.
Ferma boasts features that make it stand out from other AI-powered chat platforms with: answers grounded in real-world data and cited resources with each answer; unparalleled understanding of life sciences language and terminology backed by ZoomRx’s industry-tested knowledge graph; real-time access to critical sourcing that includes 4M scientific publications, 190k clinical trials, 30k SEC reports, 10k earnings call transcripts, 105k press releases, and much more; as well as step by step visualizations of the reasoning behind each answer to even complex questions.
“To date, the use of AI-driven language models within life sciences has been severely limited by important concerns around accuracy and data security,” stated ZoomRx Co-CEO and Co-founder Sriram Subramanian. “With the launch of Ferma, we have overcome these barriers and provided life sciences professionals with an intelligent, trustworthy ally that can provide fully sourced and confidential insights on any life sciences topic in an instant.”
Ferma’s purpose is to make research more efficient and productive, finding comprehensive answers to HCP questions with a click of a button rather than hours of searching and compiling information across multiple platforms. Ferma conversations can also be seamlessly exported to PowerPoint templates for easy data and idea sharing. Like many other AI chatbot platforms, Ferma allows any life sciences professional to try the platform for free and offers tiered pricing for subscriptions. Users can access 20 free queries per month, access to 500 queries per month, and permanent access to advanced data modules by subscribing to Ferma Pro for $100 per month or $1,000 each year, or sign up for an enterprise-level contract.
